Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Consulting agrmnt
Appointed director
Employment agrmnt
Marker Therapeutics, Inc. (MRKR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update"
08/07/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program Houston, TX – August 7, 2023 – Marker Therapeutics, Inc. , a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced non-clinical data of its lead multi-tumor-associated antigen -specific T cell product candidate, MT-401, in an Off-the-Shelf setting and provided an update on clinical readiness for the OTS program. Non-Clinical Proof-of-Concept Data of MT-401 OTS"
07/10/2023 8-K Quarterly results
06/30/2023 8-K Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits  Interactive Data
Docs: "Unaudited Pro Forma Condensed Consolidated Balance Sheet as of March 31, 2023 and Unaudited Pro Forma Condensed Consolidated Statements of Operations for the Year Ended December 31, 2021, the Year Ended December 31, 2022 and the Three Months Ended March 31, 2023"
06/12/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial"
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/31/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells"
05/08/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer"
05/01/2023 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "MARKER THERAPEUTICS announces comprehensive non-dilutive AGREEMENT WITH CELLREADY&trade"
03/22/2023 8-K Quarterly results
03/16/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/26/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Certificate of Amendment to Amended and Restated Certificate of Incorporation of Marker Therapeutics, Inc., effective January 26, 2023"
12/13/2022 8-K Quarterly results
11/22/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
10/20/2022 8-K Quarterly results
09/27/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/13/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker’ s Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML"
08/19/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
05/27/2022 8-K Quarterly results
05/13/2022 8-K Quarterly results
04/26/2022 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "Binding Services Agreement between Wilson Wolf Manufacturing Corporation and Marker Therapeutics, Inc. Dated April 21, 2022",
"MARKER THERAPEUTICS ANNOUNCES ENTRY INTO SERVICES AGREEMENT WITH WILSON WOLF HOUSTON, April 26, 2022 -- -- Marker Therapeutics, Inc. , a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced it has entered into a services agreement with Wilson Wolf Manufacturing Corporation. The agreement includes an $8.0 million upfront cash payment by Wilson Wolf to Marker in exchange for services relating to Marker’s expertise in the manufacture of cell therapies. Wilson Wolf has agreed to pay Marker an additional $1.0 million if the certain work, as defined in the services agreement, is completed within one year from the onset of the services agre..."
04/06/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/18/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
02/16/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion"
12/09/2021 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results"
08/10/2021 8-K Quarterly results
Docs: "Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results"
07/06/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML"
06/11/2021 8-K Quarterly results
05/12/2021 8-K Quarterly results
03/16/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy